Atria Investments Inc Boosts Stake in Solventum Co. (NYSE:SOLV)

Atria Investments Inc grew its position in shares of Solventum Co. (NYSE:SOLV) by 93.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 11,699 shares of the company’s stock after buying an additional 5,644 shares during the quarter. Atria Investments Inc’s holdings in Solventum were worth $816,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Davis Selected Advisers purchased a new stake in Solventum during the second quarter worth about $273,070,000. Nuance Investments LLC bought a new position in Solventum during the second quarter worth about $115,829,000. Newport Trust Company LLC bought a new position in Solventum in the 2nd quarter worth approximately $98,976,000. Baupost Group LLC MA bought a new position in Solventum in the 2nd quarter worth approximately $96,242,000. Finally, Magnetar Financial LLC grew its stake in Solventum by 2,880.8% in the 2nd quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company’s stock valued at $78,813,000 after buying an additional 1,440,410 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Wolfe Research started coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating for the company. Piper Sandler lifted their target price on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. The Goldman Sachs Group upped their price target on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research report on Monday, August 12th. BTIG Research began coverage on shares of Solventum in a research report on Thursday, September 5th. They issued a “neutral” rating for the company. Finally, Stifel Nicolaus started coverage on shares of Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $68.00.

Solventum Price Performance

SOLV stock opened at $67.12 on Tuesday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company’s 50 day moving average is $70.54 and its 200 day moving average is $62.20.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.